This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	VEGF-B	<p>Mouse studies suggest antagonizing VEGF-B could be useful for treating type 2 diabetes. In mouse models of the disease, <i>Vegf-b</i> knockouts or mice treated with an anti-Vegf-b mAb had lower lipid accumulation in peripheral tissues and greater glucose uptake than wild-type mice or mice given a control mAb. Next steps include completing preclinical toxicology studies with a humanized anti-VEGF-B mAb.</p> <p>CSL Ltd. has the humanized mAb in preclinical development for cardiovascular and metabolic indications.</p> <p>SciBX 5(41); doi:10.1038/scibx.2012.1085 Published online Oct. 18, 2012</p>	<p>Covered by issued and pending patents from CSL and the Ludwig Institute for Cancer Research Ltd.; available for partnering</p>	<p>Hagberg, C.E. <i>et al. Nature</i>; published online Sept. 26, 2012; doi:10.1038/nature11464 Contact: Ulf Eriksson, Karolinska Institute, Stockholm, Sweden e-mail: ulf.pe.eriksson@ki.se</p>